ArticleDiscover oncology2025
Impact of immune cells on renal cancer risk: a Mendelian randomization analysis with clinical cohort validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe causal relationship between immune cells and renal cancer risk remains unclear, as observational studies are susceptible to confounding factors.To evaluate the causal relationship between immune cells and renal cancer risk using Mendelian randomization (MR), and validate findings through clinical cohort studies.
methodsMR analysis was conducted based on UKB-b-1316 dataset using three methods to assess causal relationships, with focus on secreting CD4 regulatory T cells. A cohort study of 527 renal cancer patients analyzed clinical characteristics and prognostic factors.
resultsMR analysis revealed no significant causal relationship between immune cell levels and renal cancer risk overall, with most genetic instrumental variables' 95% confidence intervals crossing 1.0. Analysis of secreting CD4 regulatory T cells showed effect estimates of 0.006070 (P = 0.053) by inverse variance weighted method and 0.000695 (P = 0.024) by weighted median method, suggesting weak positive association with limited evidence. In the clinical cohort, clear cell RCC accounted for 71.7%, with median follow-up of 62.5 months and overall recurrence rate of 28.3%. Multifactorial analysis identified TNM stage ≥ T3 (HR = 3.25), Fuhrman nuclear grade ≥ 3 (HR = 2.13), histological subtype (HR = 1.87), microvascular invasion (HR = 1.78), and tumor size > 7 cm (HR = 1.56) as independent recurrence risk factors.
conclusionsMR analysis found no strong causal association between immune cells and renal cancer risk, with only CD4 regulatory T cells showing weak association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.